| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 182 | 2026 | 1957 | 14.800 |
Why?
|
| Pulmonary Artery | 65 | 2025 | 1129 | 4.740 |
Why?
|
| Hemodynamics | 59 | 2025 | 1118 | 3.910 |
Why?
|
| Ventricular Dysfunction, Right | 22 | 2026 | 248 | 3.100 |
Why?
|
| Heart Defects, Congenital | 39 | 2023 | 910 | 2.900 |
Why?
|
| Cardiac Catheterization | 43 | 2024 | 559 | 2.780 |
Why?
|
| Antihypertensive Agents | 30 | 2024 | 521 | 2.670 |
Why?
|
| Ventricular Function, Right | 24 | 2026 | 297 | 2.510 |
Why?
|
| Epoprostenol | 18 | 2022 | 132 | 2.220 |
Why?
|
| Arterial Pressure | 12 | 2025 | 134 | 2.140 |
Why?
|
| Child | 168 | 2026 | 22740 | 2.090 |
Why?
|
| Echocardiography, Three-Dimensional | 5 | 2020 | 71 | 2.090 |
Why?
|
| Vasodilator Agents | 26 | 2025 | 330 | 2.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 30 | 2024 | 196 | 2.030 |
Why?
|
| Pulmonary Circulation | 36 | 2019 | 430 | 1.680 |
Why?
|
| Child, Preschool | 105 | 2026 | 11868 | 1.680 |
Why?
|
| Vascular Resistance | 39 | 2024 | 370 | 1.670 |
Why?
|
| Heart Ventricles | 23 | 2026 | 756 | 1.650 |
Why?
|
| Echocardiography | 26 | 2026 | 648 | 1.610 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 9 | 2022 | 40 | 1.580 |
Why?
|
| Nitric Oxide | 33 | 2021 | 892 | 1.580 |
Why?
|
| Ventricular Dysfunction, Left | 15 | 2022 | 394 | 1.460 |
Why?
|
| Ventricular Function, Left | 14 | 2024 | 544 | 1.440 |
Why?
|
| Endothelin Receptor Antagonists | 11 | 2019 | 61 | 1.420 |
Why?
|
| Infant | 85 | 2024 | 10091 | 1.270 |
Why?
|
| Adolescent | 115 | 2025 | 22577 | 1.260 |
Why?
|
| Receptors, Endothelin | 9 | 2003 | 48 | 1.230 |
Why?
|
| Pulmonary Wedge Pressure | 9 | 2020 | 67 | 1.210 |
Why?
|
| Vascular Stiffness | 13 | 2023 | 487 | 1.180 |
Why?
|
| Stroke Volume | 13 | 2025 | 655 | 1.160 |
Why?
|
| Predictive Value of Tests | 29 | 2026 | 2123 | 1.150 |
Why?
|
| Altitude Sickness | 4 | 2019 | 141 | 1.130 |
Why?
|
| Humans | 244 | 2026 | 145783 | 1.110 |
Why?
|
| Natriuretic Peptide, Brain | 8 | 2021 | 109 | 1.050 |
Why?
|
| Male | 163 | 2026 | 73010 | 0.990 |
Why?
|
| Altitude | 6 | 2019 | 463 | 0.980 |
Why?
|
| Lung | 27 | 2023 | 4116 | 0.960 |
Why?
|
| Magnetic Resonance Imaging, Cine | 11 | 2025 | 214 | 0.940 |
Why?
|
| Diagnostic Imaging | 3 | 2020 | 337 | 0.940 |
Why?
|
| Actigraphy | 2 | 2024 | 148 | 0.940 |
Why?
|
| Hypoplastic Left Heart Syndrome | 10 | 2024 | 119 | 0.930 |
Why?
|
| Female | 159 | 2026 | 79045 | 0.910 |
Why?
|
| Tetralogy of Fallot | 6 | 2022 | 78 | 0.890 |
Why?
|
| Retrospective Studies | 74 | 2025 | 17330 | 0.880 |
Why?
|
| Prognosis | 33 | 2026 | 4330 | 0.870 |
Why?
|
| Sulfonamides | 9 | 2019 | 583 | 0.860 |
Why?
|
| Echocardiography, Doppler | 12 | 2018 | 115 | 0.830 |
Why?
|
| Severity of Illness Index | 26 | 2025 | 2933 | 0.810 |
Why?
|
| Fontan Procedure | 9 | 2024 | 192 | 0.790 |
Why?
|
| Aorta | 13 | 2024 | 440 | 0.760 |
Why?
|
| Eisenmenger Complex | 4 | 2019 | 13 | 0.710 |
Why?
|
| Vasodilation | 11 | 2021 | 521 | 0.710 |
Why?
|
| Administration, Inhalation | 26 | 2021 | 571 | 0.690 |
Why?
|
| Endothelin-1 | 10 | 2012 | 181 | 0.670 |
Why?
|
| Blood Proteins | 2 | 2013 | 239 | 0.660 |
Why?
|
| Age Factors | 21 | 2025 | 3346 | 0.660 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2021 | 376 | 0.650 |
Why?
|
| Receptor, Endothelin B | 12 | 2012 | 43 | 0.650 |
Why?
|
| Magnetic Resonance Imaging | 20 | 2026 | 3916 | 0.640 |
Why?
|
| Infant, Newborn | 49 | 2023 | 6465 | 0.640 |
Why?
|
| Case-Control Studies | 26 | 2025 | 3634 | 0.610 |
Why?
|
| Registries | 12 | 2024 | 2410 | 0.600 |
Why?
|
| Ventricular Remodeling | 3 | 2022 | 278 | 0.600 |
Why?
|
| Heart Transplantation | 13 | 2023 | 680 | 0.590 |
Why?
|
| Peptide Fragments | 6 | 2021 | 697 | 0.590 |
Why?
|
| Treatment Outcome | 44 | 2024 | 11794 | 0.590 |
Why?
|
| Prospective Studies | 26 | 2024 | 8078 | 0.570 |
Why?
|
| Endothelins | 7 | 2003 | 61 | 0.570 |
Why?
|
| Endpoint Determination | 2 | 2018 | 85 | 0.570 |
Why?
|
| Cardiovascular Agents | 3 | 2018 | 166 | 0.560 |
Why?
|
| Pulmonary Edema | 4 | 2019 | 105 | 0.560 |
Why?
|
| Hepatopulmonary Syndrome | 4 | 2018 | 23 | 0.540 |
Why?
|
| Phenylpropionates | 2 | 2022 | 27 | 0.530 |
Why?
|
| Oxygen | 13 | 2018 | 981 | 0.530 |
Why?
|
| Pyridazines | 2 | 2022 | 57 | 0.520 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 344 | 0.510 |
Why?
|
| Bronchopulmonary Dysplasia | 8 | 2023 | 420 | 0.510 |
Why?
|
| Critical Care | 2 | 2016 | 702 | 0.500 |
Why?
|
| Mitral Valve Stenosis | 2 | 2014 | 20 | 0.500 |
Why?
|
| SOXF Transcription Factors | 3 | 2024 | 16 | 0.500 |
Why?
|
| Biomarkers | 18 | 2021 | 4302 | 0.500 |
Why?
|
| Cause of Death | 2 | 2018 | 472 | 0.490 |
Why?
|
| Survival Rate | 17 | 2020 | 2094 | 0.480 |
Why?
|
| Mitral Valve | 3 | 2016 | 95 | 0.480 |
Why?
|
| MicroRNAs | 2 | 2020 | 686 | 0.480 |
Why?
|
| Models, Cardiovascular | 8 | 2020 | 196 | 0.470 |
Why?
|
| Cardiac Surgical Procedures | 7 | 2020 | 611 | 0.440 |
Why?
|
| Sheep | 20 | 2005 | 876 | 0.440 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 297 | 0.440 |
Why?
|
| Sildenafil Citrate | 7 | 2017 | 60 | 0.430 |
Why?
|
| Abnormalities, Multiple | 3 | 2010 | 199 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2019 | 2028 | 0.430 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 6 | 2022 | 221 | 0.420 |
Why?
|
| Image Enhancement | 2 | 2015 | 200 | 0.420 |
Why?
|
| Exercise Test | 7 | 2019 | 630 | 0.420 |
Why?
|
| Hypoxia | 12 | 2009 | 1199 | 0.410 |
Why?
|
| Ketamine | 1 | 2015 | 137 | 0.410 |
Why?
|
| Myocardial Contraction | 6 | 2020 | 293 | 0.410 |
Why?
|
| Dipyridamole | 6 | 1998 | 28 | 0.400 |
Why?
|
| Pediatrics | 8 | 2018 | 1125 | 0.400 |
Why?
|
| Prostaglandins I | 1 | 2013 | 1 | 0.400 |
Why?
|
| Protein Precursors | 6 | 2020 | 136 | 0.400 |
Why?
|
| Disease Management | 5 | 2019 | 653 | 0.390 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 26 | 0.390 |
Why?
|
| Follow-Up Studies | 23 | 2021 | 5428 | 0.390 |
Why?
|
| Connective Tissue Diseases | 2 | 2011 | 85 | 0.390 |
Why?
|
| Disease Progression | 12 | 2024 | 2865 | 0.380 |
Why?
|
| Dexmedetomidine | 1 | 2013 | 47 | 0.380 |
Why?
|
| Pulmonary Ventilation | 1 | 2013 | 82 | 0.380 |
Why?
|
| Down Syndrome | 4 | 2022 | 525 | 0.380 |
Why?
|
| Risk Assessment | 16 | 2019 | 3752 | 0.380 |
Why?
|
| Blood Flow Velocity | 14 | 2024 | 421 | 0.380 |
Why?
|
| Fetus | 12 | 2018 | 804 | 0.370 |
Why?
|
| Blood Pressure | 19 | 2019 | 1782 | 0.370 |
Why?
|
| Norwood Procedures | 2 | 2024 | 33 | 0.370 |
Why?
|
| Carbolines | 1 | 2012 | 35 | 0.360 |
Why?
|
| Sulfones | 5 | 2014 | 127 | 0.350 |
Why?
|
| Heart Atria | 4 | 2021 | 141 | 0.350 |
Why?
|
| Atrial Function, Right | 4 | 2025 | 14 | 0.350 |
Why?
|
| Phosphodiesterase Inhibitors | 5 | 2010 | 73 | 0.340 |
Why?
|
| Aorta, Thoracic | 4 | 2021 | 286 | 0.340 |
Why?
|
| Iloprost | 2 | 2010 | 45 | 0.340 |
Why?
|
| Cardiology | 4 | 2017 | 362 | 0.340 |
Why?
|
| Aortic Coarctation | 3 | 2018 | 78 | 0.340 |
Why?
|
| Calcium Channel Blockers | 3 | 2016 | 166 | 0.330 |
Why?
|
| Pulmonary Veins | 4 | 2023 | 108 | 0.330 |
Why?
|
| Heart Failure | 7 | 2023 | 2326 | 0.320 |
Why?
|
| Exercise Tolerance | 6 | 2016 | 283 | 0.320 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 2 | 2021 | 22 | 0.320 |
Why?
|
| Young Adult | 28 | 2021 | 14254 | 0.320 |
Why?
|
| Heterotaxy Syndrome | 1 | 2010 | 14 | 0.320 |
Why?
|
| Cardiac Output | 7 | 2017 | 179 | 0.310 |
Why?
|
| Piperazines | 5 | 2014 | 375 | 0.310 |
Why?
|
| Bacteremia | 2 | 2009 | 222 | 0.310 |
Why?
|
| Heart Septal Defects | 2 | 2026 | 12 | 0.300 |
Why?
|
| Quality of Life | 2 | 2020 | 3211 | 0.290 |
Why?
|
| Survival Analysis | 10 | 2020 | 1378 | 0.290 |
Why?
|
| Cohort Studies | 11 | 2024 | 6033 | 0.290 |
Why?
|
| Principal Component Analysis | 3 | 2024 | 194 | 0.290 |
Why?
|
| Portal Vein | 1 | 2010 | 117 | 0.290 |
Why?
|
| Hospitalization | 2 | 2019 | 2461 | 0.280 |
Why?
|
| Tricuspid Valve | 4 | 2017 | 43 | 0.280 |
Why?
|
| Risk Factors | 21 | 2025 | 10919 | 0.280 |
Why?
|
| Systole | 8 | 2022 | 181 | 0.270 |
Why?
|
| Heart Neoplasms | 1 | 2008 | 56 | 0.270 |
Why?
|
| Diagnosis, Differential | 7 | 2014 | 1512 | 0.270 |
Why?
|
| T-Box Domain Proteins | 2 | 2019 | 106 | 0.270 |
Why?
|
| Endothelin B Receptor Antagonists | 2 | 2005 | 12 | 0.270 |
Why?
|
| Time Factors | 20 | 2024 | 7134 | 0.270 |
Why?
|
| Vasoconstriction | 5 | 2004 | 216 | 0.270 |
Why?
|
| Colorado | 10 | 2020 | 4556 | 0.270 |
Why?
|
| Cysts | 1 | 2008 | 112 | 0.260 |
Why?
|
| Animals, Newborn | 5 | 2004 | 896 | 0.260 |
Why?
|
| Age of Onset | 4 | 2020 | 557 | 0.260 |
Why?
|
| Catheterization, Central Venous | 1 | 2009 | 123 | 0.260 |
Why?
|
| Reproducibility of Results | 12 | 2025 | 3418 | 0.260 |
Why?
|
| Anastomosis, Surgical | 4 | 2021 | 162 | 0.260 |
Why?
|
| Hypertension, Portal | 3 | 2018 | 66 | 0.260 |
Why?
|
| Electrocardiography | 4 | 2023 | 668 | 0.250 |
Why?
|
| Fetal Diseases | 3 | 2003 | 194 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2020 | 849 | 0.250 |
Why?
|
| Oxygen Consumption | 4 | 2017 | 719 | 0.250 |
Why?
|
| Receptor, Endothelin A | 7 | 2012 | 60 | 0.240 |
Why?
|
| Adult | 28 | 2023 | 40881 | 0.240 |
Why?
|
| Global Health | 5 | 2019 | 403 | 0.240 |
Why?
|
| Ontario | 4 | 2020 | 90 | 0.240 |
Why?
|
| Infant, Premature, Diseases | 2 | 2019 | 113 | 0.240 |
Why?
|
| Tunica Intima | 2 | 2007 | 78 | 0.240 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2023 | 356 | 0.230 |
Why?
|
| Regional Blood Flow | 5 | 2021 | 514 | 0.230 |
Why?
|
| Perfusion Imaging | 3 | 2024 | 66 | 0.230 |
Why?
|
| Cytokines | 2 | 2012 | 2069 | 0.230 |
Why?
|
| Morbidity | 3 | 2019 | 322 | 0.230 |
Why?
|
| Cardiomyopathies | 2 | 2009 | 335 | 0.220 |
Why?
|
| Glycogen Storage Disease Type IV | 1 | 2005 | 4 | 0.220 |
Why?
|
| 1,4-alpha-Glucan Branching Enzyme | 1 | 2005 | 4 | 0.220 |
Why?
|
| Diastole | 7 | 2022 | 146 | 0.220 |
Why?
|
| Pulse Wave Analysis | 4 | 2018 | 267 | 0.220 |
Why?
|
| Interleukin-6 | 3 | 2021 | 780 | 0.220 |
Why?
|
| Multimodal Imaging | 1 | 2026 | 129 | 0.220 |
Why?
|
| Animals | 41 | 2019 | 38101 | 0.210 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2005 | 90 | 0.210 |
Why?
|
| Home Nursing | 2 | 2003 | 24 | 0.210 |
Why?
|
| Feasibility Studies | 6 | 2024 | 1115 | 0.210 |
Why?
|
| Pulmonary Valve Insufficiency | 2 | 2022 | 48 | 0.210 |
Why?
|
| Transposition of Great Vessels | 2 | 2017 | 41 | 0.210 |
Why?
|
| Patient Selection | 2 | 2019 | 739 | 0.210 |
Why?
|
| Acetamides | 1 | 2024 | 41 | 0.210 |
Why?
|
| Gene Deletion | 2 | 2019 | 392 | 0.200 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2024 | 251 | 0.200 |
Why?
|
| Infusions, Intravenous | 5 | 2019 | 428 | 0.200 |
Why?
|
| Pyrazines | 1 | 2024 | 94 | 0.200 |
Why?
|
| Endothelial Growth Factors | 1 | 2003 | 62 | 0.200 |
Why?
|
| Prostaglandins | 5 | 2022 | 94 | 0.200 |
Why?
|
| Hypertrophy, Right Ventricular | 7 | 2020 | 149 | 0.190 |
Why?
|
| Pyrimidines | 2 | 2019 | 530 | 0.190 |
Why?
|
| Linear Models | 8 | 2016 | 849 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 1062 | 0.190 |
Why?
|
| Lung Transplantation | 5 | 2019 | 332 | 0.190 |
Why?
|
| Lymphokines | 1 | 2003 | 128 | 0.190 |
Why?
|
| Muscle, Smooth, Vascular | 6 | 2012 | 450 | 0.190 |
Why?
|
| Persistent Fetal Circulation Syndrome | 8 | 2015 | 138 | 0.190 |
Why?
|
| Drug Administration Schedule | 6 | 2020 | 782 | 0.190 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2023 | 19 | 0.190 |
Why?
|
| Piperidines | 2 | 2004 | 222 | 0.190 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 3 | 2021 | 17 | 0.190 |
Why?
|
| Heart Rate | 4 | 2024 | 856 | 0.190 |
Why?
|
| Cyclic GMP | 3 | 2019 | 90 | 0.190 |
Why?
|
| Oligopeptides | 2 | 2004 | 267 | 0.190 |
Why?
|
| Stress, Mechanical | 8 | 2019 | 494 | 0.180 |
Why?
|
| Animals, Genetically Modified | 4 | 2005 | 247 | 0.180 |
Why?
|
| Ventricular Function | 2 | 2021 | 53 | 0.180 |
Why?
|
| Rats | 13 | 2013 | 5585 | 0.180 |
Why?
|
| Angiostatic Proteins | 1 | 2021 | 4 | 0.180 |
Why?
|
| Exercise | 2 | 2024 | 2205 | 0.170 |
Why?
|
| Cross-Sectional Studies | 10 | 2021 | 5925 | 0.170 |
Why?
|
| Postoperative Complications | 5 | 2020 | 2977 | 0.170 |
Why?
|
| Aortic Valve Stenosis | 2 | 2019 | 256 | 0.170 |
Why?
|
| Drug Approval | 2 | 2019 | 93 | 0.170 |
Why?
|
| Walk Test | 2 | 2024 | 82 | 0.170 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 16 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 971 | 0.170 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2002 | 52 | 0.170 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 428 | 0.170 |
Why?
|
| Incidence | 7 | 2017 | 2934 | 0.170 |
Why?
|
| Nitric Oxide Synthase | 6 | 2002 | 234 | 0.170 |
Why?
|
| Stakeholder Participation | 2 | 2019 | 85 | 0.170 |
Why?
|
| RNA, Messenger | 5 | 2002 | 2805 | 0.170 |
Why?
|
| Hyaline Membrane Disease | 2 | 1998 | 20 | 0.170 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 4568 | 0.170 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 1998 | 17 | 0.170 |
Why?
|
| Endothelin A Receptor Antagonists | 3 | 2012 | 24 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2020 | 8 | 0.160 |
Why?
|
| ROC Curve | 3 | 2018 | 618 | 0.160 |
Why?
|
| Purines | 5 | 2014 | 187 | 0.160 |
Why?
|
| Double Outlet Right Ventricle | 2 | 2012 | 9 | 0.160 |
Why?
|
| Matrix Metalloproteinases | 1 | 2021 | 95 | 0.160 |
Why?
|
| Patient-Specific Modeling | 2 | 2020 | 45 | 0.160 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 1330 | 0.160 |
Why?
|
| Analysis of Variance | 4 | 2018 | 1300 | 0.160 |
Why?
|
| Pulmonary Gas Exchange | 3 | 2013 | 116 | 0.160 |
Why?
|
| Hernia, Diaphragmatic | 4 | 2008 | 67 | 0.150 |
Why?
|
| Gastroesophageal Reflux | 1 | 2022 | 237 | 0.150 |
Why?
|
| Heart Function Tests | 1 | 2019 | 59 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2017 | 289 | 0.150 |
Why?
|
| Respiration, Artificial | 6 | 2017 | 714 | 0.150 |
Why?
|
| Alprostadil | 2 | 2003 | 29 | 0.150 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2019 | 15 | 0.150 |
Why?
|
| Observer Variation | 3 | 2018 | 357 | 0.150 |
Why?
|
| Thrombosis | 1 | 2003 | 400 | 0.150 |
Why?
|
| Jacobsen Distal 11q Deletion Syndrome | 2 | 2009 | 2 | 0.150 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2017 | 62 | 0.150 |
Why?
|
| Genetic Variation | 3 | 2019 | 977 | 0.150 |
Why?
|
| Dilatation, Pathologic | 3 | 2018 | 61 | 0.150 |
Why?
|
| Research Subjects | 1 | 2019 | 41 | 0.140 |
Why?
|
| HLA-DP alpha-Chains | 1 | 2018 | 4 | 0.140 |
Why?
|
| Atrial Natriuretic Factor | 2 | 1996 | 55 | 0.140 |
Why?
|
| Septal Occluder Device | 1 | 2019 | 37 | 0.140 |
Why?
|
| Scurvy | 1 | 2019 | 17 | 0.140 |
Why?
|
| Anatomy | 1 | 2019 | 31 | 0.140 |
Why?
|
| Marfan Syndrome | 1 | 2018 | 46 | 0.140 |
Why?
|
| Catheters, Indwelling | 2 | 2009 | 96 | 0.140 |
Why?
|
| Aortic Diseases | 1 | 2020 | 125 | 0.140 |
Why?
|
| HLA-DP beta-Chains | 1 | 2018 | 88 | 0.140 |
Why?
|
| Tadalafil | 2 | 2022 | 6 | 0.140 |
Why?
|
| Gene Expression | 3 | 2003 | 1478 | 0.130 |
Why?
|
| Heart Bypass, Right | 1 | 2018 | 17 | 0.130 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2018 | 51 | 0.130 |
Why?
|
| Reference Values | 7 | 2017 | 798 | 0.130 |
Why?
|
| Thermodilution | 1 | 2017 | 16 | 0.130 |
Why?
|
| Turner Syndrome | 1 | 2018 | 65 | 0.130 |
Why?
|
| Infant, Premature | 5 | 2023 | 620 | 0.130 |
Why?
|
| Patients | 1 | 2019 | 183 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 3 | 2011 | 318 | 0.130 |
Why?
|
| Gestational Age | 8 | 2004 | 990 | 0.130 |
Why?
|
| Algorithms | 3 | 2016 | 1851 | 0.130 |
Why?
|
| Blood Pressure Determination | 3 | 2008 | 145 | 0.130 |
Why?
|
| Drug and Narcotic Control | 1 | 2017 | 24 | 0.130 |
Why?
|
| Pulmonary Valve | 1 | 2019 | 102 | 0.130 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2018 | 94 | 0.130 |
Why?
|
| Research Personnel | 1 | 2019 | 185 | 0.130 |
Why?
|
| Vasomotor System | 4 | 2006 | 47 | 0.130 |
Why?
|
| Blotting, Northern | 4 | 2002 | 203 | 0.130 |
Why?
|
| Vascular Capacitance | 1 | 2016 | 4 | 0.130 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2012 | 271 | 0.120 |
Why?
|
| Heart Failure, Systolic | 1 | 2017 | 26 | 0.120 |
Why?
|
| Blood Vessels | 2 | 2013 | 167 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 410 | 0.120 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2017 | 75 | 0.120 |
Why?
|
| Travel | 1 | 2018 | 136 | 0.120 |
Why?
|
| Arterial Switch Operation | 1 | 2017 | 16 | 0.120 |
Why?
|
| Exome | 1 | 2018 | 229 | 0.120 |
Why?
|
| Echocardiography, Doppler, Pulsed | 2 | 2016 | 14 | 0.120 |
Why?
|
| United States | 13 | 2025 | 16126 | 0.120 |
Why?
|
| Anticoagulants | 3 | 2011 | 748 | 0.120 |
Why?
|
| Proteomics | 2 | 2014 | 1188 | 0.120 |
Why?
|
| Administration, Oral | 5 | 2020 | 867 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 783 | 0.120 |
Why?
|
| Ultrasonography, Interventional | 1 | 1998 | 166 | 0.120 |
Why?
|
| Vascular Remodeling | 1 | 2018 | 209 | 0.120 |
Why?
|
| Hypertension | 1 | 2005 | 1276 | 0.120 |
Why?
|
| Endothelin-3 | 1 | 1996 | 3 | 0.120 |
Why?
|
| Arteries | 1 | 2018 | 261 | 0.120 |
Why?
|
| United States Food and Drug Administration | 2 | 2017 | 208 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2017 | 224 | 0.120 |
Why?
|
| Health Information Systems | 1 | 2016 | 16 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 552 | 0.120 |
Why?
|
| Forecasting | 1 | 2018 | 390 | 0.120 |
Why?
|
| Coronary Care Units | 1 | 2016 | 27 | 0.120 |
Why?
|
| Nitrous Oxide | 1 | 2016 | 34 | 0.120 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 77 | 0.120 |
Why?
|
| Echinococcosis, Pulmonary | 1 | 2015 | 7 | 0.120 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1998 | 185 | 0.110 |
Why?
|
| Endothelium, Vascular | 3 | 2021 | 956 | 0.110 |
Why?
|
| Growth Disorders | 1 | 2016 | 89 | 0.110 |
Why?
|
| Mitral Valve Prolapse | 1 | 1995 | 9 | 0.110 |
Why?
|
| Anesthetics | 1 | 2016 | 100 | 0.110 |
Why?
|
| Chemokine CCL2 | 2 | 2012 | 112 | 0.110 |
Why?
|
| Fibroblasts | 3 | 2013 | 1028 | 0.110 |
Why?
|
| Chronic Disease | 8 | 2010 | 1812 | 0.110 |
Why?
|
| Elasticity | 7 | 2015 | 189 | 0.110 |
Why?
|
| Heart | 1 | 2019 | 626 | 0.110 |
Why?
|
| Drug Therapy, Combination | 4 | 2022 | 1043 | 0.110 |
Why?
|
| Hemorrhage | 2 | 2019 | 822 | 0.110 |
Why?
|
| Body Height | 1 | 2016 | 203 | 0.110 |
Why?
|
| Ductus Arteriosus | 5 | 2000 | 72 | 0.110 |
Why?
|
| Computer Systems | 1 | 2014 | 55 | 0.110 |
Why?
|
| Peptides, Cyclic | 4 | 1998 | 273 | 0.110 |
Why?
|
| Probability | 4 | 2008 | 308 | 0.110 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1995 | 124 | 0.110 |
Why?
|
| Cardiomegaly | 3 | 2008 | 174 | 0.100 |
Why?
|
| Angina Pectoris, Variant | 1 | 1994 | 3 | 0.100 |
Why?
|
| Ventricular Septum | 2 | 2015 | 8 | 0.100 |
Why?
|
| Ebstein Anomaly | 1 | 1993 | 7 | 0.100 |
Why?
|
| Dogs | 1 | 2015 | 478 | 0.100 |
Why?
|
| Netherlands | 1 | 2013 | 84 | 0.100 |
Why?
|
| Health Policy | 1 | 2017 | 400 | 0.100 |
Why?
|
| Contrast Media | 1 | 2017 | 497 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2018 | 1491 | 0.100 |
Why?
|
| Lung Diseases | 4 | 2016 | 782 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2013 | 92 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 381 | 0.100 |
Why?
|
| Analgesics | 1 | 2015 | 231 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 920 | 0.100 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 288 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2015 | 229 | 0.100 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 78 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1582 | 0.100 |
Why?
|
| Pain | 1 | 2019 | 791 | 0.100 |
Why?
|
| Homeodomain Proteins | 2 | 2008 | 523 | 0.100 |
Why?
|
| Biopsy | 1 | 2016 | 1082 | 0.100 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 2012 | 45 | 0.090 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 74 | 0.090 |
Why?
|
| Shear Strength | 4 | 2018 | 73 | 0.090 |
Why?
|
| Equipment Contamination | 2 | 2009 | 67 | 0.090 |
Why?
|
| Thromboembolism | 2 | 2005 | 129 | 0.090 |
Why?
|
| Endostatins | 2 | 2021 | 10 | 0.090 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 1271 | 0.090 |
Why?
|
| Myocardial Ischemia | 1 | 1994 | 285 | 0.090 |
Why?
|
| Arteritis | 1 | 2012 | 23 | 0.090 |
Why?
|
| Ultrasonography, Doppler | 3 | 2012 | 126 | 0.090 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 1995 | 235 | 0.090 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 58 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2009 | 219 | 0.090 |
Why?
|
| Mutation | 3 | 2019 | 4090 | 0.090 |
Why?
|
| Decision Making | 1 | 2019 | 982 | 0.090 |
Why?
|
| Research Design | 2 | 2015 | 1139 | 0.080 |
Why?
|
| Biomechanical Phenomena | 4 | 2018 | 860 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2018 | 583 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 1547 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2015 | 517 | 0.080 |
Why?
|
| In Situ Hybridization | 2 | 2002 | 318 | 0.080 |
Why?
|
| Bronchodilator Agents | 2 | 2005 | 187 | 0.080 |
Why?
|
| Syndrome | 3 | 2024 | 381 | 0.080 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 354 | 0.080 |
Why?
|
| Chromosome Mapping | 2 | 2009 | 507 | 0.080 |
Why?
|
| Interleukin-10 | 1 | 2012 | 311 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2002 | 203 | 0.080 |
Why?
|
| Phagocytes | 1 | 2011 | 80 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1752 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 261 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2011 | 251 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2010 | 7 | 0.080 |
Why?
|
| Mesoderm | 1 | 2011 | 147 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2011 | 147 | 0.080 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2015 | 390 | 0.080 |
Why?
|
| Liver Cirrhosis | 2 | 2018 | 288 | 0.080 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 196 | 0.080 |
Why?
|
| Graft Rejection | 2 | 2010 | 521 | 0.080 |
Why?
|
| Natriuretic Peptides | 1 | 2009 | 9 | 0.080 |
Why?
|
| Proteome | 1 | 2014 | 513 | 0.080 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2009 | 26 | 0.080 |
Why?
|
| Liver Transplantation | 3 | 2018 | 827 | 0.080 |
Why?
|
| Acetylcholine | 4 | 2001 | 209 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2020 | 50 | 0.070 |
Why?
|
| Area Under Curve | 3 | 2017 | 332 | 0.070 |
Why?
|
| Palliative Care | 4 | 2018 | 1022 | 0.070 |
Why?
|
| Heart Diseases | 2 | 2011 | 341 | 0.070 |
Why?
|
| Gram-Positive Bacteria | 1 | 2009 | 48 | 0.070 |
Why?
|
| Uncertainty | 1 | 2010 | 146 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 892 | 0.070 |
Why?
|
| Primary Graft Dysfunction | 1 | 2009 | 33 | 0.070 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 49 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2009 | 80 | 0.070 |
Why?
|
| Neurogranin | 1 | 2008 | 2 | 0.070 |
Why?
|
| Heart Septum | 1 | 2008 | 27 | 0.070 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2009 | 72 | 0.070 |
Why?
|
| Perioperative Care | 2 | 2012 | 231 | 0.070 |
Why?
|
| Home Infusion Therapy | 1 | 2008 | 4 | 0.070 |
Why?
|
| Pregnancy | 10 | 2012 | 7216 | 0.070 |
Why?
|
| Monocrotaline | 2 | 2005 | 31 | 0.070 |
Why?
|
| Respiratory Function Tests | 2 | 2008 | 544 | 0.070 |
Why?
|
| Prevalence | 4 | 2018 | 2875 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2011 | 527 | 0.070 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2008 | 38 | 0.070 |
Why?
|
| Nitroarginine | 6 | 2001 | 57 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 217 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2016 | 2447 | 0.060 |
Why?
|
| Fatal Outcome | 3 | 2003 | 305 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2007 | 55 | 0.060 |
Why?
|
| Time | 2 | 2005 | 84 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2023 | 2770 | 0.060 |
Why?
|
| Inflammation | 3 | 2013 | 2884 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 740 | 0.060 |
Why?
|
| Cognition | 1 | 2015 | 1271 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 2000 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2023 | 152 | 0.060 |
Why?
|
| Infusions, Subcutaneous | 2 | 2019 | 23 | 0.060 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2009 | 198 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2007 | 37 | 0.060 |
Why?
|
| Safety | 2 | 2005 | 358 | 0.060 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2005 | 11 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2013 | 1509 | 0.060 |
Why?
|
| Risk | 2 | 2019 | 923 | 0.060 |
Why?
|
| Logistic Models | 4 | 2013 | 2139 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 2191 | 0.060 |
Why?
|
| Amylopectin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 2399 | 0.060 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2007 | 138 | 0.060 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2003 | 58 | 0.060 |
Why?
|
| Middle Aged | 8 | 2020 | 36309 | 0.060 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2004 | 15 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 592 | 0.050 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2004 | 21 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2015 | 2064 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2005 | 117 | 0.050 |
Why?
|
| Europe | 2 | 2017 | 421 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2008 | 788 | 0.050 |
Why?
|
| Patient Safety | 2 | 2019 | 356 | 0.050 |
Why?
|
| Sample Size | 1 | 2024 | 121 | 0.050 |
Why?
|
| Respiration Disorders | 1 | 2005 | 78 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2008 | 544 | 0.050 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2015 | 37 | 0.050 |
Why?
|
| Graft Survival | 2 | 2010 | 519 | 0.050 |
Why?
|
| Pulse Therapy, Drug | 1 | 2003 | 7 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2004 | 94 | 0.050 |
Why?
|
| Rats, Mutant Strains | 1 | 2003 | 19 | 0.050 |
Why?
|
| Parturition | 1 | 2004 | 69 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2014 | 1001 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2003 | 78 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2003 | 94 | 0.050 |
Why?
|
| Physical Examination | 1 | 2005 | 244 | 0.050 |
Why?
|
| Monitoring, Physiologic | 2 | 2018 | 289 | 0.050 |
Why?
|
| Birth Weight | 1 | 2006 | 517 | 0.050 |
Why?
|
| Isoxazoles | 1 | 2003 | 56 | 0.050 |
Why?
|
| Anesthesia | 1 | 2007 | 257 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2004 | 1049 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2003 | 78 | 0.050 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 558 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 3937 | 0.050 |
Why?
|
| Capillary Permeability | 1 | 2003 | 132 | 0.050 |
Why?
|
| Nitrogen | 1 | 2003 | 125 | 0.050 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 85 | 0.050 |
Why?
|
| Thiophenes | 1 | 2003 | 117 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2007 | 411 | 0.050 |
Why?
|
| Comorbidity | 2 | 2018 | 1662 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 2 | 2000 | 93 | 0.050 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2002 | 17 | 0.050 |
Why?
|
| Computer Simulation | 3 | 2016 | 1003 | 0.040 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2002 | 65 | 0.040 |
Why?
|
| Constriction | 2 | 2003 | 45 | 0.040 |
Why?
|
| Galectin 3 | 1 | 2021 | 21 | 0.040 |
Why?
|
| American Heart Association | 1 | 2023 | 358 | 0.040 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2001 | 13 | 0.040 |
Why?
|
| Radioligand Assay | 1 | 2001 | 36 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2003 | 298 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 162 | 0.040 |
Why?
|
| Rats, Inbred Strains | 1 | 2001 | 321 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2003 | 1184 | 0.040 |
Why?
|
| Liver | 1 | 2009 | 1899 | 0.040 |
Why?
|
| Angiography | 2 | 1999 | 208 | 0.040 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2021 | 211 | 0.040 |
Why?
|
| Labor, Obstetric | 1 | 2001 | 68 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2012 | 1736 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 1723 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 3170 | 0.040 |
Why?
|
| Ligation | 2 | 2000 | 91 | 0.040 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2020 | 34 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 59 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2020 | 134 | 0.040 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2019 | 12 | 0.040 |
Why?
|
| Enzyme Inhibitors | 5 | 2004 | 821 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2008 | 1171 | 0.040 |
Why?
|
| Respiratory Insufficiency | 2 | 2001 | 327 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2009 | 59 | 0.040 |
Why?
|
| Gingiva | 1 | 2019 | 25 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 80 | 0.040 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2019 | 44 | 0.040 |
Why?
|
| Autografts | 1 | 2019 | 55 | 0.040 |
Why?
|
| Chromosome Deletion | 2 | 2009 | 126 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 2000 | 227 | 0.040 |
Why?
|
| Blood Circulation | 1 | 1998 | 44 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 71 | 0.030 |
Why?
|
| Cholecalciferol | 1 | 2019 | 61 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 188 | 0.030 |
Why?
|
| Perfusion | 2 | 2004 | 251 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2019 | 132 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 314 | 0.030 |
Why?
|
| Chest Pain | 1 | 2019 | 99 | 0.030 |
Why?
|
| Nose | 1 | 1998 | 67 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2018 | 35 | 0.030 |
Why?
|
| Myocardium | 1 | 2023 | 935 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 169 | 0.030 |
Why?
|
| Software | 1 | 2023 | 680 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 343 | 0.030 |
Why?
|
| Masks | 1 | 1998 | 70 | 0.030 |
Why?
|
| Catheterization | 1 | 1998 | 184 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2019 | 159 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2514 | 0.030 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2018 | 82 | 0.030 |
Why?
|
| Long-Term Care | 1 | 1998 | 118 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 404 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2011 | 1165 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2018 | 388 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 2019 | 184 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2018 | 89 | 0.030 |
Why?
|
| Aftercare | 1 | 2019 | 222 | 0.030 |
Why?
|
| Government Regulation | 1 | 2017 | 39 | 0.030 |
Why?
|
| Child Advocacy | 1 | 2017 | 31 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 450 | 0.030 |
Why?
|
| Postoperative Period | 1 | 1998 | 351 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 151 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2019 | 356 | 0.030 |
Why?
|
| Oximetry | 1 | 2018 | 125 | 0.030 |
Why?
|
| Off-Label Use | 1 | 2017 | 51 | 0.030 |
Why?
|
| Vibration | 1 | 2017 | 70 | 0.030 |
Why?
|
| Leg | 1 | 2019 | 242 | 0.030 |
Why?
|
| Policy Making | 1 | 2017 | 83 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2018 | 128 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 2968 | 0.030 |
Why?
|
| Swine | 1 | 2019 | 826 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2017 | 87 | 0.030 |
Why?
|
| Clinical Competence | 2 | 2015 | 1247 | 0.030 |
Why?
|
| Aerosols | 1 | 2017 | 146 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 1247 | 0.030 |
Why?
|
| Iron | 1 | 2019 | 359 | 0.030 |
Why?
|
| Estradiol | 1 | 2000 | 515 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 463 | 0.030 |
Why?
|
| Growth Charts | 1 | 2016 | 20 | 0.030 |
Why?
|
| Arginine | 2 | 1994 | 264 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 572 | 0.030 |
Why?
|
| Particle Size | 1 | 2017 | 381 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 479 | 0.030 |
Why?
|
| Child Health | 1 | 2017 | 154 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 26 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2019 | 305 | 0.030 |
Why?
|
| Hypertension, Renal | 1 | 1995 | 15 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 364 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2019 | 401 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2018 | 364 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1997 | 115 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2021 | 878 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 161 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 2015 | 99 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2015 | 80 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2018 | 403 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2005 | 2525 | 0.030 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2015 | 61 | 0.030 |
Why?
|
| Home Care Services | 1 | 1998 | 284 | 0.030 |
Why?
|
| Rats, Long-Evans | 2 | 2006 | 128 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2021 | 935 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2018 | 5224 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 381 | 0.030 |
Why?
|
| Acute Disease | 3 | 2005 | 1036 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 584 | 0.030 |
Why?
|
| Viper Venoms | 1 | 1994 | 6 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 2131 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1995 | 318 | 0.030 |
Why?
|
| Endothelium | 1 | 1995 | 119 | 0.030 |
Why?
|
| Muscle Tonus | 1 | 1994 | 24 | 0.030 |
Why?
|
| Aged | 3 | 2020 | 26217 | 0.030 |
Why?
|
| Competency-Based Education | 1 | 2015 | 81 | 0.030 |
Why?
|
| Length of Stay | 2 | 2012 | 1350 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 1994 | 14 | 0.030 |
Why?
|
| Nifedipine | 1 | 1994 | 27 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 693 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2015 | 181 | 0.020 |
Why?
|
| Goals | 1 | 2015 | 185 | 0.020 |
Why?
|
| Alberta | 1 | 2013 | 25 | 0.020 |
Why?
|
| Models, Biological | 1 | 2020 | 1764 | 0.020 |
Why?
|
| Teaching | 1 | 2015 | 237 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2013 | 450 | 0.020 |
Why?
|
| Administration, Intravenous | 1 | 2013 | 172 | 0.020 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2012 | 9 | 0.020 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2012 | 19 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2015 | 520 | 0.020 |
Why?
|
| Stents | 2 | 2009 | 564 | 0.020 |
Why?
|
| Bronchi | 1 | 2013 | 263 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1430 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2015 | 326 | 0.020 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2011 | 24 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 528 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 136 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2011 | 87 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 172 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2181 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2011 | 86 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 319 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 365 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2011 | 99 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 507 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 2110 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 900 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 770 | 0.020 |
Why?
|
| Recurrence | 1 | 1994 | 1139 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 962 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 306 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2013 | 501 | 0.020 |
Why?
|
| Guanidines | 2 | 2001 | 39 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2010 | 121 | 0.020 |
Why?
|
| Hyaluronic Acid | 1 | 2012 | 226 | 0.020 |
Why?
|
| Mice | 4 | 2009 | 18355 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2001 | 162 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1361 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2011 | 386 | 0.020 |
Why?
|
| Tricuspid Atresia | 1 | 2008 | 4 | 0.020 |
Why?
|
| Venae Cavae | 1 | 2008 | 7 | 0.020 |
Why?
|
| Monocytes | 1 | 2012 | 539 | 0.020 |
Why?
|
| Vena Cava, Superior | 1 | 2008 | 25 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2008 | 117 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 1043 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 2009 | 94 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2014 | 719 | 0.020 |
Why?
|
| Curriculum | 1 | 2015 | 1074 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 177 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 360 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2013 | 933 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1708 | 0.020 |
Why?
|
| Tunica Media | 1 | 2007 | 37 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2007 | 108 | 0.020 |
Why?
|
| Diseases in Twins | 1 | 2008 | 116 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2007 | 67 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 1038 | 0.020 |
Why?
|
| Fibrosis | 1 | 2009 | 561 | 0.020 |
Why?
|
| Child Development | 1 | 2012 | 483 | 0.020 |
Why?
|
| Stem Cells | 1 | 2011 | 630 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1777 | 0.020 |
Why?
|
| Partial Pressure | 1 | 2005 | 30 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 5992 | 0.010 |
Why?
|
| Drug Synergism | 2 | 1998 | 354 | 0.010 |
Why?
|
| Deferoxamine | 1 | 2005 | 27 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2006 | 187 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2005 | 77 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2005 | 168 | 0.010 |
Why?
|
| Cross Infection | 1 | 2008 | 260 | 0.010 |
Why?
|
| Reoperation | 1 | 2008 | 637 | 0.010 |
Why?
|
| Common Bile Duct | 1 | 2004 | 14 | 0.010 |
Why?
|
| Compliance | 1 | 2004 | 50 | 0.010 |
Why?
|
| Liver Failure | 1 | 2005 | 83 | 0.010 |
Why?
|
| Protoporphyrins | 1 | 2004 | 16 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 853 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1482 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2015 | 1269 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 399 | 0.010 |
Why?
|
| Metalloporphyrins | 1 | 2004 | 63 | 0.010 |
Why?
|
| Hematocrit | 1 | 2004 | 108 | 0.010 |
Why?
|
| Compressive Strength | 1 | 2004 | 72 | 0.010 |
Why?
|
| Tensile Strength | 1 | 2004 | 98 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 927 | 0.010 |
Why?
|
| rho-Associated Kinases | 1 | 2004 | 82 | 0.010 |
Why?
|
| Amides | 1 | 2004 | 101 | 0.010 |
Why?
|
| Polytetrafluoroethylene | 1 | 2003 | 23 | 0.010 |
Why?
|
| Ventilator Weaning | 1 | 2003 | 40 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 31 | 0.010 |
Why?
|
| Hyperoxia | 1 | 2004 | 107 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2002 | 52 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 53 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 3130 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 1898 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2003 | 165 | 0.010 |
Why?
|
| Waiting Lists | 1 | 2003 | 266 | 0.010 |
Why?
|
| Amidines | 1 | 2001 | 13 | 0.010 |
Why?
|
| Benzylamines | 1 | 2001 | 44 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 457 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 668 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2000 | 69 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 999 | 0.010 |
Why?
|
| Pyridines | 1 | 2004 | 609 | 0.010 |
Why?
|
| Calcium | 1 | 2005 | 1191 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 1454 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2000 | 153 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1999 | 249 | 0.010 |
Why?
|
| Isothiuronium | 1 | 1998 | 3 | 0.010 |
Why?
|
| Thiazines | 1 | 1998 | 13 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 4151 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1996 | 38 | 0.010 |
Why?
|
| Methylene Blue | 1 | 1996 | 24 | 0.010 |
Why?
|
| Indomethacin | 1 | 1996 | 76 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1996 | 82 | 0.010 |
Why?
|
| Adenosine | 1 | 1998 | 255 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1996 | 153 | 0.010 |
Why?
|
| Pressure | 1 | 1996 | 226 | 0.010 |
Why?
|
| Purinones | 1 | 1995 | 4 | 0.010 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 1995 | 10 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1995 | 30 | 0.010 |
Why?
|
| Theophylline | 1 | 1995 | 41 | 0.010 |
Why?
|
| Arterioles | 1 | 1995 | 52 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1995 | 84 | 0.010 |
Why?
|
| Phenylephrine | 1 | 1995 | 74 | 0.010 |
Why?
|
| Heart Rate, Fetal | 1 | 1995 | 31 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1993 | 79 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1995 | 563 | 0.010 |
Why?
|